Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (URGN)
NASDAQ:URGN
Earnings Data
Report Date
May 07, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.5Last Year’s EPS
-0.92Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed meaningful positive commercial and clinical momentum: a material ramp in revenue driven by Jelmyto and the Zasturi launch (21% total revenue growth in 2025), clear evidence of early adoption acceleration following a permanent J‑code, robust Phase 3 data for next‑generation programs (UGN‑103) with a defined regulatory path, and a refinancing that strengthens liquidity and extends runway. Offsetting these positives are a widening net loss, higher R&D and projected operating expenses in 2026, and continued uncertainty because no formal 2026 sales guidance for Zasturi was provided. On balance, the highlights — especially commercial acceleration, clinical success and improved balance sheet — outweigh the lowlights, but execution in 2026 will be critical to translate early momentum into durable financial improvement.Company Guidance
Zasturi Early Commercial Traction and Permanent J‑Code
Zasturi generated $15,800,000 in net product revenue in 2025 (Q3 $1.8M; Q4 $14.0M). Permanent, product‑specific J‑code became effective January 1, 2026, and management reported a clear acceleration in key launch indicators (new/repeat prescribers, patient enrollment forms, new patient starts) since that milestone.
Strong Adoption Metrics
As of 12/31/2025 there were 838 activated sites of care, 102 unique prescribers and 32 repeat prescribers. Payer execution covered >95% of covered lives by year‑end 2025. Management reported a shift toward greater community adoption (approximately 50/50 hospital vs. community as of early 2026).
Jelmyto Revenue and 2026 Guidance
Jelmyto generated $94,000,000 in net product revenue in 2025. Management provided 2026 Jelmyto net product revenue guidance of $97,000,000 to $101,000,000, implying ~3% to ~7% year‑over‑year growth.
Company Revenue Growth
Total company revenues were $109,800,000 for 2025, up from $90,400,000 in 2024 — a ~21% year‑over‑year increase driven by Zasturi launch plus increased Jelmyto sales.
Positive Phase 3 Clinical Data and Near‑Term Regulatory Path
UGN‑103 (next‑generation Cysitore) showed a 77.8% complete response (CR) rate at 3 months in the Utopia Phase 3 trial, consistent with ENVISION (approximately 80% CR at 3 months). ENVISION data also show Kaplan‑Meier estimates of ~80% disease‑free at 12 months and ~72% at 24 months. Management plans an NDA submission for UGN‑103 in 2026 with potential approval in 2027.
Pipeline Progress and Multiple Upcoming Milestones
UGN‑104 Phase 3 enrollment expected to complete by 2026. UGN‑501 IND‑enabling work underway with plan to submit IND and start Phase 1 in 2026. Management expects Type C FDA meetings and intends to pursue additional indications (high‑grade and adjuvant settings) for UGN‑103.
Refinancing Strengthens Balance Sheet and Financial Flexibility
Entered a second amended and restated loan agreement providing a $250,000,000 senior secured term loan facility (two tranches). $200,000,000 initial tranche funded at closing (used to refinance prior loan and provide nondilutive capital); second $50,000,000 tranche drawable through 06/30/2027. Interest fixed at 8.25% with principal repayments beginning in 2030. Management stated this enhances financial flexibility to support launch and pipeline execution.
Operational Feedback and Patient/Physician Reception
Anecdotal feedback from early adopters indicated Zasturi integrates smoothly into routine practice (simple outpatient six‑dose regimen, predictable workflow) and patients appreciate a nonsurgical outpatient option. Management reported February 2026 indicators surpassed Jelmyto early launch metrics.
URGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
URGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 02, 2026 | $21.70 | $19.02 | -12.35% |
Nov 06, 2025 | $19.31 | $23.54 | +21.91% |
Aug 07, 2025 | $20.01 | $18.59 | -7.10% |
May 12, 2025 | $10.38 | $11.14 | +7.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Urogen Pharma (URGN) report earnings?
Urogen Pharma (URGN) is schdueled to report earning on May 07, 2026, Before Open (Confirmed).
What is Urogen Pharma (URGN) earnings time?
Urogen Pharma (URGN) earnings time is at May 07, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is URGN EPS forecast?
URGN EPS forecast for the fiscal quarter 2026 (Q1) is -0.5.